Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Protein Degradation Specialist Gets $1bn Up Front

 
• By Mandy Jackson

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Stand out from the crowd
Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy

More from Deals

More from Business